港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

轩竹生物-B

63.600

-0.350-0.55%

成交量：33.68万

成交额：2,124.75万

市值：329.41亿

市盈率：-47.11

高：63.900

开：63.900

低：62.500

收：63.950

52周最高：72.000

52周最低：23.820

股本：5.18亿

香港流通股本：1.61亿

量比：0.99

换手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):-1.350

净资产收益率：--

总资产收益率：--

市净率：35.62

市盈率(LYR):-47.11

市销率: 942.75

数据加载中...

总览公司新闻资讯公告

吡洛西利亮相ESMO，轩竹生物-B(2575.HK)国产创新药的突围样本

格隆汇资讯

港股综述｜三大指数齐跌！黄金股集体大跌，老铺黄金跌逾8%；轩竹生物-B飙涨近32%续刷上市新高

老虎资讯综合

轩竹生物-B10月22日获主力加仓3885.0万元

港股异动 | 轩竹生物-B涨幅扩大至31%，吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布

《股市简讯》中国轩竹生物劲扬逾两成，一款抗癌药临床试验显示积极效果

港股异动 | 生物技术股大涨，轩竹生物涨超18%

老虎资讯综合

轩竹生物-B(02575)：吡洛西利一线治疗HR+/HER2-晚期乳腺癌临床III期研究数据于2025年ESMO公布

轩竹生物-B10月21日主力净流入348.7万元散户资金抛售

港股异动 | 轩竹生物-B(02575)拉升逾14% 较招股价已涨超2.3倍公司今年迎来商业化爆发期

医药生物行业跟踪周报：高股息创新中药标的被低估重点推荐佐力药业、方盛制药等

烟台财金集团收获年内第5家IPO企业，轩竹生物登陆港交所主板

【机构】健康使命港股启航 | 国友大正助力轩竹生物擘画创新药发展新格局

中国资产评估协会

合肥市创业投资引导基金投资企业轩竹生物成功登陆港交所

轩竹生物-B涨逾15%，较招股价涨超180%！公司拥超过十余种正在研发的药物管线

老虎资讯综合

多只医药新股上市头日收涨超100%！包括曾申报科创板IPO未果的新股

异动解读 | 轩竹生物-B盘中大涨5.17%，新药研发及商业化进展获市场认可

异动解读 | 轩竹生物-B上市次日大跌6.54%，或因获利回吐及估值调整

异动解读 | 轩竹生物-B上市次日盘中大跌6.54%，高开低走或因获利回吐

港股综述 | 科指涨2.57%，阿里涨近4%；三花智控涨近13%，轩竹生物首日飙升126%

老虎资讯综合

大涨167%！A股、港股，盘中异动！

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02575/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":63.6,"timestamp":1763366893772,"preClose":63.95,"halted":0,"volume":336804,"delay":0,"floatShares":160701996,"shares":517947790,"eps":-1.3501580822288384,"marketStatus":"已收盘","change":-0.35,"latestTime":"11-17 16:08:13","open":63.9,"high":63.9,"low":62.5,"amount":21247494,"amplitude":0.021892,"askPrice":63.65,"askSize":2500,"bidPrice":63.2,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.3499929789103007,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":63.95,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.994732,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":-1.350158,"volumeRatio":0.994732,"shares":517947790,"dividePrice":0,"high":63.9,"amplitude":0.021892,"preClose":63.95,"low":62.5,"week52Low":23.82,"pbRate":"35.62","psRate":"942.75","week52High":72,"institutionHeld":0,"latestPrice":63.6,"committee":-0.666667,"eps":-1.3501580822288384,"divideRate":0,"volume":336804,"delay":0,"ttmEps":-1.3499929789103007,"open":63.9,"prevYearClose":11.6,"prevWeekClose":63.95,"prevMonthClose":63.6,"prevQuarterClose":11.6,"fiveDayClose":66.2,"twentyDayClose":33.9,"sixtyDayClose":11.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2025-11-14","current":-46.796344,"percent":0.428571,"low":-59.374256,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"high":-22.444691,"avg":-48.666426,"sd":11.257814,"marketCap":33122761170},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170}],"updateTime":1763353038723},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577347347","title":"吡洛西利亮相ESMO，轩竹生物-B(2575.HK)国产创新药的突围样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2577347347","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577347347?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 10:17","pubTimestamp":1761185834,"startTime":"0","endTime":"0","summary":"轩竹生物股价开盘持续攀升，收涨31.87%，创下股价新高，这一走势直接反映出市场对此次临床数据的认可，以及对公司后续发展的信心。回溯今年5月，该药已获国家药监局批准两项适应症。其一，轩竹生物吡洛西利的一线ORR显著优于同类产品的中国患者数据。其二，吡洛西利单药获批的独特性形成商业化护城河。结语吡洛西利在ESMO的亮相，本质是国产创新药从“跟跑”向“领跑”转变的缩影。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023101727a6c8fb58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023101727a6c8fb58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","02575","BK1574"],"gpt_icon":1},{"id":"1104795850","title":"港股综述｜三大指数齐跌！黄金股集体大跌，老铺黄金跌逾8%；轩竹生物-B飙涨近32%续刷上市新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1104795850","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104795850?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 16:30","pubTimestamp":1761121800,"startTime":"0","endTime":"0","summary":"港股行情港股收评：恒指跌近1%！科技股、生物医药股普遍弱势，黄金股跌幅明显10月22日，港股三大指数集体收跌未能延续反弹行情，恒生科技指数一度跌至2.3%，最终收跌1.41%失守6000点关口，恒生指数跌0.94%同样跌破26000点大关，国企指数跌0.85%报9223点。深地经济概念逆势崛起，贵金属板块领跌10月22日，A股主要指数今日小幅走低，截至收盘，沪指跌0.07%报3913点，深证成指跌0.62%，创业板指跌0.79%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06181","HSTECH","HSI","02068","02575","09992"],"gpt_icon":1},{"id":"2577935964","title":"轩竹生物-B10月22日获主力加仓3885.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577935964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577935964?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 16:16","pubTimestamp":1761120961,"startTime":"0","endTime":"0","summary":"10月22日, 轩竹生物-B股价涨31.87%，报收60.00元，成交金额2.8亿元，换手率3.08%，振幅34.07%，量比0.96。轩竹生物-B今日主力资金净流入3885.0万元，上一交易日主力净流入348.7万元。该股近5个交易日上涨128.14%，主力资金累计净流入6035.0万元；近20日主力资金累计净流入6035.0万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022162144a46e0ed0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022162144a46e0ed0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2577330139","title":"港股异动 | 轩竹生物-B涨幅扩大至31%，吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2577330139","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577330139?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 14:52","pubTimestamp":1761115946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午后涨幅进一步扩大，盘中高见59.85港元，较招股价11.6港元已涨超415%。消息面上，轩竹生物宣布，其已于德国当地时间10月20日在2025年欧洲肿瘤内科学会上，以壁报的形式展示了吡洛西利联合来曲唑或阿那曲唑在HR+/HER2-晚期乳腺癌一线治疗的临床III期期中分析结果。据悉，BRIGHT-3研究是一项在中国58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的有效性和安全性。","market":"fut","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f6dbeba4b9216bf67b1faa04c809b62c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357993.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 轩竹生物-B涨幅扩大至31%，吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK4134"],"gpt_icon":0},{"id":"2577338602","title":"《股市简讯》中国轩竹生物劲扬逾两成，一款抗癌药临床试验显示积极效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2577338602","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577338602?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 10:38","pubTimestamp":1761100700,"startTime":"0","endTime":"0","summary":"《股市简讯》中国轩竹生物劲扬逾两成，一款抗癌药临床试验显示积极效果* 中国生物科技公司--轩竹生物2575.HK周三早盘大涨23.1%。* 该公司此前公告称，吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的三期临床试验的期中分析显示，吡洛西利组有更多患者仍未发生疾病进展，反映出其持久的疗效优势。* 恒⽣⽣物科技指数.HSBIO盘中一度跌1.5%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 林高丽) ((kaiwen.xu@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nL4T3W305S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1121439883","title":"港股异动 | 生物技术股大涨，轩竹生物涨超18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121439883","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121439883?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 09:58","pubTimestamp":1761098330,"startTime":"0","endTime":"0","summary":"10月22日，港股$生物(000504)$技术股大涨，$轩竹生物-B(02575)$涨超18%，创上市以来新高，$药捷安康-B(02617)$涨超16%，$博安生物(06955)$、$同源康医药-B(02410)$跟涨。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"069d3331287d7c7ffedd7cde87c41b57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2577456383","title":"轩竹生物-B(02575)：吡洛西利一线治疗HR+/HER2-晚期乳腺癌临床III期研究数据于2025年ESMO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2577456383","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577456383?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 06:27","pubTimestamp":1761085679,"startTime":"0","endTime":"0","summary":"BRIGHT-3研究是一项在中国58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的有效性和安全性。基于BRIGHT-3研究中期数据，中国国家药品监督管理局已于2025年5月14日正式受理吡洛西利联合芳香化酶抑制剂治疗HR+/HER2-晚期乳腺癌的新药上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4203","III","BK4134","02575","BK4225","HR"],"gpt_icon":1},{"id":"2577923842","title":"轩竹生物-B10月21日主力净流入348.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2577923842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577923842?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 16:15","pubTimestamp":1761034522,"startTime":"0","endTime":"0","summary":"10月21日, 轩竹生物-B股价涨33.82%，报收45.50元，成交金额8368.5万元，换手率1.36%，振幅35.59%，量比0.00。轩竹生物-B今日主力资金净流入348.7万元，上一交易日主力净流出55.1万元。该股近5个交易日上涨296.55%，主力资金累计净流入2150.0万元；近20日主力资金累计净流入2150.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021161636a6c571db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021161636a6c571db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2577843315","title":"港股异动 | 轩竹生物-B(02575)拉升逾14% 较招股价已涨超2.3倍 公司今年迎来商业化爆发期","url":"https://stock-news.laohu8.com/highlight/detail?id=2577843315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577843315?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 13:40","pubTimestamp":1761025242,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B午后涨超14%，高见38.8港元，较招股价11.6港元已涨超234%。截至发稿，涨12.12%，报38.12港元，成交额3229.15万港元。招股书显示，轩竹生物由港股上市公司四环医药分拆而来，为典型的“H拆H”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d70afcf9629808e93bd5e43b692d3cbf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":1},{"id":"2576262076","title":"医药生物行业跟踪周报：高股息创新中药标的被低估 重点推荐佐力药业、方盛制药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2576262076","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576262076?lang=zh_cn&edition=fundamental","pubTime":"2025-10-19 00:00","pubTimestamp":1760803200,"startTime":"0","endTime":"0","summary":"三生制药眼科创新药申报上市；第一三共MUC1 ADC 首个临床数据公开。震荡市场下中药板块高股息凸显性价比，推荐佐力药业，方盛制药等：中药上市公司现金流充沛，现金储备也相对丰富。推荐佐力药业、华润三九、方盛制药等仍处于快速成长、且兼具高股息标的。具体标的选择思路：从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510192051279736deed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510192051279736deed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","02228","01530","BK1141","BK1617","06978"],"gpt_icon":0},{"id":"2576283033","title":"烟台财金集团收获年内第5家IPO企业，轩竹生物登陆港交所主板","url":"https://stock-news.laohu8.com/highlight/detail?id=2576283033","media":"齐鲁壹点","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576283033?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 17:37","pubTimestamp":1760693852,"startTime":"0","endTime":"0","summary":"10月15日，烟台财金集团投资企业轩竹生物科技股份有限公司在港交所主板正式敲锣上市。上市首日轩竹生物开盘后即呈现高开态势，开盘价29.46港元/股，较发行价11.60港元/股上涨153.97%，总市值超150亿港元。继长风药业后，轩竹生物成为集团2025年收获的第五家IPO企业。轩竹生物作为一家深耕生物医药领域的创新型企业，始终专注于创新药物的研发、生产与商业化。截至目前，集团已推动39家企业登陆资本市场，助力41家企业进入上市辅导阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101717430194cee5a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101717430194cee5a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":1},{"id":"2576033237","title":"【机构】健康使命 港股启航 | 国友大正助力轩竹生物擘画创新药发展新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2576033237","media":"中国资产评估协会","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576033237?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 17:09","pubTimestamp":1760692178,"startTime":"0","endTime":"0","summary":"轩竹生物以未满足的临床需求为导向，致力于发展成为具有自主研发、生产和销售能力的一流创新药企业。此次募资7.8亿港元，将为轩竹生物创新药物的研发、生产与商业化注入强劲动能，助力核心创新药产品惠及全球患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017175134a464ed22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017175134a464ed22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1161","BK1574","06978"],"gpt_icon":1},{"id":"2576083492","title":"合肥市创业投资引导基金投资企业轩竹生物成功登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2576083492","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576083492?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 13:58","pubTimestamp":1760680739,"startTime":"0","endTime":"0","summary":"来源：市场资讯 10月15日，合肥市创业投资引导基金参股子基金先进制造产业投资基金二期投资企业——轩竹生物科技股份有限公司成功登陆香港联合交易所主板。轩竹生物科技股份有限公司成立于2018年，是一家以创新为驱动、致力于改善患者健康和生活质量的中国生物制药公司。轩竹生物通过“自主研发 + 对外授权”的双轨模式快速推进药物商业化，已累计获得20项IND批准，并提交或获批7项NDA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101714033694ce829e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101714033694ce829e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":1},{"id":"1183774161","title":"轩竹生物-B涨逾15%，较招股价涨超180%！公司拥超过十余种正在研发的药物管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1183774161","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183774161?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 10:29","pubTimestamp":1760668186,"startTime":"0","endTime":"0","summary":"10月17日，次新股$轩竹生物-B$盘中拉升逾15%，较招股价涨超180%！公开资料显示，轩竹生物是一家以创新为驱动的中国生物制药公司。截至最后实际可行日期，公司有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和非酒精性脂肪性肝炎，包括三项NDA批准资产，一个药物项目处于NDA注册阶段，一个药物项目处于III期临床试验阶段，四个药物项目处于I期临床试验阶段，五个已获IND批准。轩竹生物此次全球发售所得款项净额约为7.01亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"47feaade0fe516d289883e4adde0d41e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2575530714","title":"多只医药新股上市头日收涨超100%！包括曾申报科创板IPO未果的新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575530714","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575530714?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 16:58","pubTimestamp":1760605089,"startTime":"0","endTime":"0","summary":"银诺医药的暴涨更凸显了市场对核心创新资产的追捧。中国已成为全球第二大医药市场，其中创新药领域增长尤为迅猛。医药研发具有周期长、投入大、风险高的特点，一款新药从临床前研究到上市平均需投入 10 亿美元以上，成功率不足 10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016170328a462f942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016170328a462f942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","02575","BK1161","09939","00460","BK1515","BK1574"],"gpt_icon":1},{"id":"1109943861","title":"异动解读 | 轩竹生物-B盘中大涨5.17%，新药研发及商业化进展获市场认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1109943861","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109943861?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 15:00","pubTimestamp":1760598034,"startTime":"0","endTime":"0","summary":"10月16日，轩竹生物-B股价盘中大涨5.17%，延续了其上市以来的强劲表现。该公司于10月15日在港交所挂牌上市，上市首日即大涨126.72%，显示出投资者对这家创新生物制药公司的高度认可。尽管轩竹生物目前仍处于亏损阶段，但其商业化进程正在加速。市场普遍认为，随着公司产品线的不断丰富和商业化能力的提升，轩竹生物有望在未来实现快速增长。此次上市融资约7.01亿港元，将进一步支持公司的研发和商业化战略，为其长远发展奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"gpt_icon":1},{"id":"1153186772","title":"异动解读 | 轩竹生物-B上市次日大跌6.54%，或因获利回吐及估值调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1153186772","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153186772?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 09:34","pubTimestamp":1760578467,"startTime":"0","endTime":"0","summary":"港股新上市公司轩竹生物-B今日盘中大跌6.54%，引发市场关注。该公司昨日刚在港交所挂牌上市，首日表现强劲，收盘大涨126.72%。轩竹生物是一家创新驱动的生物制药公司，专注于消化系统疾病、肿瘤和非酒精性脂肪性肝炎等领域的药物研发。公司目前已有三款商业化产品，并拥有超过十种在研药物资产。尽管短期内股价出现波动，但投资者在关注该股时，需要同时考虑其创新能力、商业化进展以及整体行业环境等多重因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"gpt_icon":0},{"id":"1100747627","title":"异动解读 | 轩竹生物-B上市次日盘中大跌6.54%，高开低走或因获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1100747627","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100747627?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 09:32","pubTimestamp":1760578351,"startTime":"0","endTime":"0","summary":"港股新上市公司轩竹生物-B今日盘中大跌6.54%，引发市场关注。该公司昨日刚在港交所挂牌上市，首日表现强劲，收盘大涨126.72%。轩竹生物是一家创新驱动的生物制药公司，专注于消化系统疾病、肿瘤和非酒精性脂肪性肝炎等领域的药物研发。公司目前已有三款商业化产品，并拥有超过十种在研药物资产。尽管收入呈增长趋势，但公司仍处于亏损状态。虽然短期内股价出现波动，但轩竹生物的长期发展前景仍值得关注。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"gpt_icon":0},{"id":"1176591756","title":"港股综述 | 科指涨2.57%，阿里涨近4%；三花智控涨近13%，轩竹生物首日飙升126%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176591756","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176591756?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 16:43","pubTimestamp":1760517801,"startTime":"0","endTime":"0","summary":"港股行情港股三大指数集体上涨，恒生科技指数涨2.57%重回6000点大关，恒生指数、国企指数分别上涨1.84%及1.89%。另一方面，影视股、海运股、稀土概念股少部分板块低迷，此外，$轩竹生物-B$首日上市大幅收涨126.72%。个股方面：由四环医药分拆的$轩竹生物-B$今日首日上市，大涨126.72%，报26.3港元。A股行情A股三大指数齐升，上证指数涨1.22%重回3900点，深证成指涨1.73%，创业板指大涨2.36%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f4119f815e17ed8243f86d7bacc114d6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","HSI","00981","02575","02050","01211"],"gpt_icon":1},{"id":"2575208788","title":"大涨167%！A股、港股，盘中异动！","url":"https://stock-news.laohu8.com/highlight/detail?id=2575208788","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575208788?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 14:46","pubTimestamp":1760510775,"startTime":"0","endTime":"0","summary":"创新药，集体异动！今日（10月15日），在港股市场上，创新药概念股大幅异动，新股轩竹生物一度暴涨167%，若不计手续费，每手（500股）最高可赚约9700港元。在A股市场上，创新药概念股也集体拉升，亚太药业、昂利康、济民健康等多股涨停。港股新股大涨10月15日，创新药概念股轩竹生物在港交所挂牌上市，该股开盘报29.46港元/股，较发行价（11.60港元/股）上涨153.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510153534810925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","PPI","ALK","BK4588","BK4500","BK1574","BK4570","02575","BK4585","06978","BK4008"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}]}}